Below is an announcement regarding AstraZeneca 's first patent application on DEP® Bcl2/xL conjugates. It is the first of several patent applications
Why do I bring this up know.
It is not a secret.
Well the operative words here are "first of several patent applications"
Preparing and submitting patent applications is a process which involves time and money.
AstraZeneca are serious or they would not go out there to protect their (Starpharma/AstraZeneca collaborative IP)
So what do I take issue with (a question for the CEO of Starpharma at AGM.......hopefully one of the holders from this forum will ask the question)
It is the time line.....starting in October 2017 .....early next year (calendar year 2018) and with no time line in latest October 2018 update
Just to reiterate AstraZeneca's first of several patents......several being the operative word
Surely based on below information........either trial will start sometime before end of calendar year 2018.......or we need to ask what is the reason for delay......based on Jackie's initial start time of early 2018. Even though AstraZeneca control timing of beginning of trial........it was obvious from first announcment released to ASX more than a year ago.......the CEO was very confident of trial initiation in early half of calendar year 2018
Below is some background on the query in question
We can go as far back as the interview conducted by Morgans Finance Limited (Morgans Senior Analyst Scott Power) ......."Under The Microscope with CEO Dr Jackie Fairley 23/10/17
Quotes taken from interview......"That particular product (AZD0046) is going into Phase 1 trials early next year" (calendar year 2018)
Repeated later on in interview....."That trial will commence in 2018 first half" (AZD0046).....obviously referring to calendar year 2018
"AZD0466 is funded by AstraZeneca and clinical trials are expected to commence in 2018".......Share holder update 19/02/18
"Clinical trials for AZD0466 are expected to commence in 2018" (open to interpretation.......as financial year 2018......one can only speculate within the next 6 weeks.......source half yearly annual report 2018) 26/02/18
We can go as far back as the interview conducted by Commsec (Tom Potrowski) Executive Series 14/03/18
"Our AstraZeneca partnership goes from strength to strength and continues to really move along in a very positive manner............ As well as having that lead product (AZD0046) going into the clinic....which we expect that will occur within the next few months" (remember these statements were released in March of 2018).
"AstraZeneca recently filed patents which incorporated the dendrimer technology........that patents have a 20 year lifespan"
"Dep Irinotecan will go into phase 1 towards the end of the year" (obviously referring to calendar year 2018)
AstraZeneca’s DEP Bcl2/xL inhibitors show compelling efficacy and synergy in combination 31/08/18.........No mention of AZD0466 going into clinical phase 1 trial
Starpharma Investor Presentation for Citi Conference 23/10/18..........once again not mention of time line of AZD0046 going into clinical trial
Below is part of the 31/08/18 announcement referring to the first of several patent applications
AstraZeneca’s first of several patent applications on Starpharma’s DEP®dendrimer with AstraZeneca’s Bcl2/xL inhibitors has been published, showing compelling results
DEP® Bcl2/xL conjugates demonstrate better anti-cancer activity than Bcl2/xL inhibitor alone in multiple cancer models
DEP® Bcl2/xL conjugates in combination with leading current anti-cancert reatments provide substantial improvements in efficacy in multiple leukemia models
Melbourne, Australia; 31 August 2018:
Starpharma (ASX: SPL, OTCQX: SPHRY) today announced AstraZeneca’s first patent application on DEP® Bcl2/xL conjugates has been published by the World Intellectual Property Organisation. These DEP® Bcl2/xL conjugates combine Starpharma’s innovative DEP® delivery technology with AstraZeneca’s novelmBcl2/xL inhibitor for treating various cancers, including leukemias.
The published patent application shows compelling efficacy data on DEP® Bcl2/xL conjugates, both alone and in combination with other leading current anti-cancer treatments, in various preclinical human tumour models.
As announced on 28 September 2017, AstraZeneca describes its DEP® Bcl2/xL conjugate, AZD0466, as “best-in-class” with a broad combination opportunity in both solid and
haematological tumours (blood cancers)
1. Bcl2 is a clinically validated oncology target withth e leukemia drug venetoclax (Venclexta® - AbbVie/Genentech) approved by the US FDA in20 16. Peak global sales of venetoclax are projected to be greater than US$7 billion
2. However, venetoclax has only anti-Bcl2 activity and its efficacy may be limited becausec ancer cells are potentially able to exploit a parallel survival mechanism
3. Therefore, targeting both Bcl2 and Bcl/xL (as AstraZeneca’s novel DEP® Bcl2/xL conjugate AZD0466 does), and using it in combination with other therapies, are attractive strategies that may overcome problematic drug resistance which occurs in many human cancers and therebypr ovide better efficacy.
Starpharma CEO, Dr Jackie Fairley commented:
“AstraZeneca’s impressive data published today demonstrates that the DEP® Bcl2/xL conjugates are highly effective across a range of cancer types both alone and in combination with other anti-cancer agents. Especially exciting for Starpharma is the combination with blockbuster products such as Rituximab, where the DEP® Bcl2/xL conjugates, including AZD0466 showed a strong synergistic effect. Given the synergy appears to also occur with other leading anti-cancer drugs this could represent an important additional benefit for the DEP® platform”.
“The data published in this patent demonstrates that AstraZeneca’s science-driven approach to identifying optimal combinations for its oncology portfolio has delivered outstanding results. We’re very pleased that Starpharma’s DEP® technology makes an important contribution to the performance of these exciting oncology candidates. This first patent application incorporating the novel DEP® Bcl2/xL conjugates developed under our .................
Comments are welcome
SPL Price at posting:
$1.59 Sentiment: Buy Disclosure: Held
(20min delay)
